Emtricitabine 200 mg / rilpivirine 25 mg / tenofovir alafenamide 25 mg Oral Tablet
RxNorm 1741733

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 1741733 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: emtricitabine 200 mg / rilpivirine 25 mg / tenofovir alafenamide 25 mg Oral Tablet.

The following semantic concepts and normalized strings are associated with this clinical entity:

SCD
Emtricitabine 200 mg / rilpivirine 25 mg / tenofovir alafenamide 25 mg Oral Tablet
Primary clinical definition
AUI:12333541
View
SY
Emtricitabine 200 mg / rilpivirine 25 mg (as rilpivirine HCl 27.5 mg) / tenofovir alafenamide 25 mg (as tenofovir alafenamide fumarate 28 mg) Oral Tablet
AUI:7742931
View
PSN
Emtricitabine 200 mg / rilpivirine 25 mg / tenofovir alafenamide 25 mg Oral Tablet
AUI:7742982
View
PT
Emtricitabine 200 mg and rilpivirine (as rilpivirine hydrochloride) 25 mg and tenofovir alafenamide (as tenofovir alafenamide fumarate) 25 mg oral tablet
AUI:12902476
View
FN
Product containing precisely emtricitabine 200 mg and rilpivirine (as rilpivirine hydrochloride) 25 mg and tenofovir alafenamide (as tenofovir alafenamide fumarate) 25 mg/1 each conventional release oral tablet (clinical drug)
AUI:12903758
View

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

SCDPrescribable

Semantic Clinical Drug (SCD):
Emtricitabine 200 mg / rilpivirine 25 mg / tenofovir alafenamide 25 mg Oral Tablet
(Atom ID: 12333541)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
emtricitabine 200 MG / rilpivirine 25 MG / tenofovir alafenamide 25 MG Oral Tablet
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
1741733
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12333541
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SCD
Semantic Clinical Drug (Ingredient + Strength + Dose Form)
Source Code
1741733
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Technical Attributes & Logic

RXN AI
{1102271} 1102287
RXCUI of BOSS Active Ingredient preceded by RXCUI of SCDC responsible for value
RXN AI
{1741729} 1721604
RXCUI of BOSS Active Ingredient preceded by RXCUI of SCDC responsible for value
RXN AI
{406016} 276237
RXCUI of BOSS Active Ingredient preceded by RXCUI of SCDC responsible for value
RXN AM
{1102271} 1102270
RXCUI of BOSS Active Moiety preceded by RXCUI of SCDC responsible for value
RXN AM
{1741729} 1721603
RXCUI of BOSS Active Moiety preceded by RXCUI of SCDC responsible for value
RXN AM
{406016} 276237
RXCUI of BOSS Active Moiety preceded by RXCUI of SCDC responsible for value
RXN AVAILABLE STRENGTH
200 MG / 25 MG / 25 MG
Available drug strengths listed in the order of ingredients from the drug
RXN BOSS FROM
{1102271} AM
Source of BOSS as either from the active ingredient (AI) or the active moiety (AM) preceded by RXCUI of SCDC responsible for value
RXN BOSS FROM
{1741729} AM
Source of BOSS as either from the active ingredient (AI) or the active moiety (AM) preceded by RXCUI of SCDC responsible for value
RXN BOSS FROM
{406016} AI
Source of BOSS as either from the active ingredient (AI) or the active moiety (AM) preceded by RXCUI of SCDC responsible for value
RXN HUMAN DRUG
US
Drug available for use in Humans
RXTERM FORM
Tab
The RxTerm dose form name for this drug
SYPrescribable

Synonym (SY):
Emtricitabine 200 mg / rilpivirine 25 mg (as rilpivirine HCl 27.5 mg) / tenofovir alafenamide 25 mg (as tenofovir alafenamide fumarate 28 mg) Oral Tablet
(Atom ID: 7742931)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
emtricitabine 200 MG / rilpivirine 25 MG (as rilpivirine HCl 27.5 MG) / tenofovir alafenamide 25 MG (as tenofovir alafenamide fumarate 28 MG) Oral Tablet
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
1741733
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
7742931
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SY
Synonym (Synonym of another TTY, given for clarity.)
Source Code
1741733
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.
PSNPrescribable

Prescribable Name (PSN):
Emtricitabine 200 mg / rilpivirine 25 mg / tenofovir alafenamide 25 mg Oral Tablet
(Atom ID: 7742982)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
emtricitabine 200 MG / rilpivirine 25 MG / tenofovir alafenamide 25 MG Oral Tablet
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
1741733
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
7742982
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
PSN
Prescribable Name (Synonym of another TTY, given for clarity and for display purposes in electronic prescribing applications. Only one PSN per concept.)
Source Code
1741733
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.
PTPrescribable

Designated preferred name (PT):
Emtricitabine 200 mg and rilpivirine (as rilpivirine hydrochloride) 25 mg and tenofovir alafenamide (as tenofovir alafenamide fumarate) 25 mg oral tablet
(Atom ID: 12902476)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
Emtricitabine 200 mg and rilpivirine (as rilpivirine hydrochloride) 25 mg and tenofovir alafenamide (as tenofovir alafenamide fumarate) 25 mg oral tablet
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
1741733
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12902476
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
PT
Designated preferred name ()
Source Code
1304318008
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
US Edition of SNOMED CT (SNOMEDCT_US)
The official name and abbreviation for the vocabulary source.
Source Version
2026_01_31
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
National Library Of Medicine, NLM is a Charter Member of SNOMED International on behalf of the U.S., National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, 1-888-FIND-NLM (1-888-346-3656), , https://support.nlm.nih.gov/support/create-case/,
Source licensing contact information.
FNPrescribable

Full form of descriptor (FN):
Product containing precisely emtricitabine 200 mg and rilpivirine (as rilpivirine hydrochloride) 25 mg and tenofovir alafenamide (as tenofovir alafenamide fumarate) 25 mg/1 each conventional release oral tablet (clinical drug)
(Atom ID: 12903758)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
Product containing precisely emtricitabine 200 milligram and rilpivirine (as rilpivirine hydrochloride) 25 milligram and tenofovir alafenamide (as tenofovir alafenamide fumarate) 25 milligram/1 each conventional release oral tablet (clinical drug)
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
1741733
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12903758
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
FN
Full form of descriptor ()
Source Code
1304318008
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
US Edition of SNOMED CT (SNOMEDCT_US)
The official name and abbreviation for the vocabulary source.
Source Version
2026_01_31
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
National Library Of Medicine, NLM is a Charter Member of SNOMED International on behalf of the U.S., National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, 1-888-FIND-NLM (1-888-346-3656), , https://support.nlm.nih.gov/support/create-case/,
Source licensing contact information.

Patient Education

Emtricitabine, Rilpivirine, and Tenofovir


The combination of emtricitabine, rilpivirine, and tenofovir is used to treat HIV in adults and children who weigh at least 77 pounds (35 kilograms). Emtricitabine, rilpivirine, and tenofovir are in a class of medications called nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs). They work by slowing the spread of HIV in the body. Although emtricitabine, rilpivirine, and tenofovir will not cure HIV, these medications may decrease your chance of developing acquired immunodeficiency syndrome (AIDS) and HIV-related illnesses such as serious infections or cancer. Taking these medications along with practicing safer sex and making other lifestyle changes may decrease the risk of getting or transmitting the HIV virus to other people.
[Learn More]


* Please review the disclaimer below.